Hjem › Plasmacellekreft › New York
Kliniske studier for Plasmacellekreft i New York
6 studier for Plasmacellekreft søker deltakere på steder i New York.
Byer i New York
Offisiell studietekst (engelsk)
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Mount Sinai, The Tisch Cancer Instutute, New York
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04879043MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT06152575A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Memorial Sloan-Kettering Cancer Center, New York
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT05651932Delayed Toxicities Post-CAR-T
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT07665307A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- og 1 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 26. mai 2026 · NCT07052916Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
- University of Rochester, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. feb. 2025 · NCT05597345Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.